Fresenius Medical Care AG & Co. KGaA (DE:FME)
XETRA:FME
Want to see DE:FME full AI Analyst Report?
FME Stock Chart & Stats
€38.69
-€0.05(-0.11%)
At close: 4:00 PM EST
€38.69
-€0.05(-0.11%)
Day’s Range― - ―
52-Week Range€34.57 - €54.02
Previous CloseN/A
Volume12.09K
Average Volume (3M)529.60K
Market Cap
€10.41B
Enterprise Value€8.77B
Total Cash (Recent Filing)€1.73B
Total Debt (Recent Filing)€13.70B
Price to Earnings (P/E)22.5
Beta0.58
Next Earnings
Aug 05, 2026EPS Estimate
1.05Next Dividend Ex-DateN/A
Dividend Yield3.54%
Share Statistics
EPS (TTM)3.37
Shares Outstanding293,413,450
10 Day Avg. Volume492,004
30 Day Avg. Volume529,597
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)0.89
Price to Sales (P/S)0.60
P/FCF Ratio6.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€38.19Price Target Upside-1.29% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering11
EPS Forecast (FY)4.03
Revenue Forecast (FY)€19.37B
Bulls Say, Bears Say
Bulls Say
Integrated Products & ServicesFresenius Medical Care’s integrated model—clinic operations plus manufacturing of machines and single-use consumables—creates recurring, treatment-linked revenue and cross-selling opportunities. That structural mix supports steady demand and utilization, cushioning revenue volatility from individual product cycles.
Consistent Operating Cash FlowStable, multi-year operating cash flow at a multi-billion-euro level provides durable funding for maintenance capex, clinic operations, and dividends. Even with FCF swings, solid operating cash generation underpins the company’s ability to service operations and sustain strategic investments over the medium term.
Profitability Rebound In 2025Meaningful margin and net income improvement in 2025 indicates successful cost controls or mix improvements and demonstrates some operational leverage in the business. If sustained, higher margins enhance resilience to reimbursement pressure and provide more internal funds for reinvestment or deleveraging.
Bears Say
Revenue ContractionA multiyear flat-to-declining top line constrains long-term growth and raises questions about volume, pricing, or payor reimbursement trends. For a capital-intensive provider, sustained revenue pressure limits scale benefits, reduces ability to expand services, and tightens margins over time.
Volatile And Declining Free Cash FlowSharp free cash flow deterioration despite rising reported earnings signals weaker cash conversion, possibly from working capital shifts or higher cash uses. Persistent FCF volatility reduces capacity to invest, pay down debt, and maintain payout policies without relying on external financing.
Rising Leverage In 2025A notable jump in absolute debt levels and reduced equity cushion materially lowers balance-sheet flexibility. Higher leverage increases interest expense sensitivity and constrains strategic options (M&A, capex, dividends) if cashflows weaken or reimbursement pressures persist.
FME FAQ
What was Fresenius Medical Care AG & Co. KGaA’s price range in the past 12 months?
Fresenius Medical Care AG & Co. KGaA lowest stock price was €34.57 and its highest was €54.02 in the past 12 months.
What is Fresenius Medical Care AG & Co. KGaA’s market cap?
Fresenius Medical Care AG & Co. KGaA’s market cap is €10.41B.
When is Fresenius Medical Care AG & Co. KGaA’s upcoming earnings report date?
Fresenius Medical Care AG & Co. KGaA’s upcoming earnings report date is Aug 05, 2026 which is in 90 days.
How were Fresenius Medical Care AG & Co. KGaA’s earnings last quarter?
Fresenius Medical Care AG & Co. KGaA released its earnings results on May 05, 2026. The company reported €0.91 earnings per share for the quarter, missing the consensus estimate of €1.012 by -€0.102.
Is Fresenius Medical Care AG & Co. KGaA overvalued?
According to Wall Street analysts Fresenius Medical Care AG & Co. KGaA’s price is currently Overvalued.
Does Fresenius Medical Care AG & Co. KGaA pay dividends?
Fresenius Medical Care AG & Co. KGaA pays a Annually dividend of €1.44 which represents an annual dividend yield of 3.54%. See more information on Fresenius Medical Care AG & Co. KGaA dividends here
What is Fresenius Medical Care AG & Co. KGaA’s EPS estimate?
Fresenius Medical Care AG & Co. KGaA’s EPS estimate is 1.05.
How many shares outstanding does Fresenius Medical Care AG & Co. KGaA have?
Fresenius Medical Care AG & Co. KGaA has 293,413,450 shares outstanding.
What happened to Fresenius Medical Care AG & Co. KGaA’s price movement after its last earnings report?
Fresenius Medical Care AG & Co. KGaA reported an EPS of €0.91 in its last earnings report, missing expectations of €1.012. Following the earnings report the stock price went down -10.677%.
Which hedge fund is a major shareholder of Fresenius Medical Care AG & Co. KGaA?
Currently, no hedge funds are holding shares in DE:FME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fresenius Medical Care AG & Co. KGaA Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.79%
12-Months-Change
Fundamentals
Return on Equity
7.26%
Trailing 12-Months
Asset Growth
-7.64%
Trailing 12-Months
Company Description
Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
FME Stock 12 Month Forecast
Average Price Target
€38.19
▼(-1.29% Downside)
Technical Analysis
Options Prices
Currently, No data available
---